Statin use and hip fractures in U.S. kidney transplant recipients

Chandan Vangala, Colin R. Lenihan, Maria E. Montez-Rath, Sumi Sukumaran Nair, Sankar D. Navaneethan, Venkat Ramanathan, Wolfgang C. Winkelmayer

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background: Basic and translational research supports beneficial effects of statins on bone metabolism. Clinical studies suggest that statin use may reduce the risk of hip fractures in the general population. Whether statin use is associated with hip fracture risk in kidney transplant recipients, a particularly high-risk group for this outcome, is unknown. Methods: From the U.S. Renal Data System (2007-2011), we identified all hip fracture events recorded in Medicare billing claims of first-time kidney transplant recipients. We then matched all cases to an unlimited number of controls on age (±3 years), sex, race (black vs. non-black), and time since transplant. Cases and controls were required to have >1 year of Medicare Parts A + B + D coverage and be without a recorded history of hip fracture. We ascertained any statin use in the previous year and defined adherent statin use as those who had filled prescriptions for statins to cover >80% of days in that year (proportion of days covered, PDC). We ascertained several potential confounders (demographics, comorbidities, BMI, transplant-related factors) and applied conditional logistic regression with multiple imputation for missing data to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: We identified 231 hip fracture cases (mean age 51.8 years; 53% female; 11.3% black; 6.9 years from transplant, and 9.9 years from ESRD) and 15,575 matched controls. Any prior statin use was present in 64.1% of cases and 60.3% of controls with 37.2% of cases and 33.9% of controls being found adherent. Unadjusted conditional logistic regression showed an OR of 1.17 (0.89-1.54) for any statin use, and a fully-adjusted OR of 0.89 (0.67-1.19). Compared with statin non-users, the adjusted OR for patients with lesser adherence (PDC ≤80%) and those with greater adherence (PDC >80%) were 0.93 (0.66-1.31) and 0.87 (0.63-1.20), respectively. Conclusion: Statin use was not associated with hip fracture risk in first-time kidney transplant recipients.

Original languageEnglish (US)
Article number145
JournalBMC Nephrology
Volume18
Issue number1
DOIs
StatePublished - May 1 2017

Keywords

  • Case-control
  • Drug safety
  • End-stage renal disease
  • Hip fracture
  • Outcomes
  • USRDS

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Statin use and hip fractures in U.S. kidney transplant recipients'. Together they form a unique fingerprint.

  • Cite this

    Vangala, C., Lenihan, C. R., Montez-Rath, M. E., Nair, S. S., Navaneethan, S. D., Ramanathan, V., & Winkelmayer, W. C. (2017). Statin use and hip fractures in U.S. kidney transplant recipients. BMC Nephrology, 18(1), [145]. https://doi.org/10.1186/s12882-017-0559-9